Autolus Therapeutics
AUTL
39 hedge funds and large institutions have $546M invested in Autolus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 13 closing their positions.
128% more capital invested
Capital invested by funds: $240M → $546M (+$306M)
23.13% more ownership
Funds ownership: 22.89% → 46.02% (+23%)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
19% less funds holding
Funds holding: 48 → 39 (-9)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$249M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$20.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$13.2M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.24M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$13.2M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$7.44M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.38M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$4.02M |
| 5 |
Millennium Management
New York
|
-$2.97M |
AUTL Hedge Fund Activity: Q3 2018 in Review
39 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2018, worth a combined $546M — up 128% from $240M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AUTL and 5 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was Woodford Investment Management, adding an estimated $249M. The largest seller was Capital World Investors, cutting an estimated $13.2M.
- 39 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2018, down from 48 in Q2 2018.
- Funds reported $546M of Autolus Therapeutics stock for Q3 2018, up 128% quarter-over-quarter.
- 5 funds opened new Autolus Therapeutics positions in Q3 2018 and 13 closed out, a net change of -8 holders.
- The largest Autolus Therapeutics buyer in Q3 2018 was Woodford Investment Management, an estimated $249M added.
- The largest Autolus Therapeutics seller in Q3 2018 was Capital World Investors, an estimated $13.2M sold.
Based on aggregated 13F filings for Q3 2018.